Biomarkers of Host Metabolic Response to Prolonged Fever

Abstract

Prolonged fever serves as a clinical hallmark of diverse infectious and non-infectious etiologies, with significant morbidity and diagnostic complexity. Recent advances in biomarker research have illuminated the metabolic adaptations and dysregulations that occur during sustained febrile responses. This review synthesizes current evidence regarding the host metabolic response to prolonged fever, focusing on key biomarkers with diagnostic, prognostic, and therapeutic relevance. Mechanism-based interpretations, emerging technologies, and guideline-driven clinical implications are discussed, providing a comprehensive resource for healthcare professionals involved in the management of patients with persistent fever.

Introduction

Fever is an adaptive physiological response to infection or inflammation, characterized by a regulated elevation in body temperature. While acute fever episodes are commonly self-limiting, prolonged fever—typically defined as fever persisting more than seven days—poses significant diagnostic and management challenges. The metabolic response to prolonged fever involves a complex interplay of cytokines, acute-phase reactants, and metabolic reprogramming. Identifying reliable biomarkers that reflect these metabolic changes is crucial for guiding clinical decision-making, risk stratification, and therapeutic interventions in affected patients.

Epidemiology / Disease Burden

Prolonged fever affects patients globally, contributing to substantial healthcare utilization and diagnostic expenditure. It is estimated that up to 10% of all hospitalized patients may experience fever of unknown origin (FUO), with prolonged cases accounting for a significant proportion. The burden is particularly pronounced in immunocompromised populations, such as oncology and transplant patients, where persistent fever may herald life-threatening complications. The increasing prevalence of multi-drug resistant organisms, autoimmune diseases, and autoinflammatory syndromes has further complicated the epidemiological landscape, underscoring the need for precise metabolic biomarkers to inform tailored management strategies.

Pathophysiology

The metabolic response to prolonged fever is orchestrated by pro-inflammatory cytokines—including IL-1, IL-6, and TNF-α—which induce a switch from anabolic to catabolic metabolism. This leads to altered glucose, lipid, and protein homeostasis, with increased gluconeogenesis, lipolysis, and muscle proteolysis. Mitochondrial dysfunction and oxidative stress are frequently observed, resulting in elevated lactate and reactive oxygen species (ROS). Acute-phase proteins such as C-reactive protein (CRP), serum amyloid A, and ferritin are upregulated, reflecting the systemic inflammatory milieu. Recent research has identified additional metabolic markers, including procalcitonin, presepsin, and metabolites like kynurenine and neopterin, as indicators of immune activation and metabolic stress during prolonged fever.

Risk Factors

Several patient-specific and disease-related factors heighten the risk of developing a pronounced metabolic response to prolonged fever. Immunosuppression due to chemotherapy, transplantation, or advanced HIV infection predisposes patients to persistent infections and aberrant inflammatory responses. Comorbidities such as diabetes mellitus and chronic kidney disease modify metabolic pathways, amplifying the clinical impact of fever. Genetic polymorphisms in cytokine and acute-phase protein genes have also been implicated in inter-individual variability in biomarker levels and fever duration, highlighting the importance of personalized approaches to biomarker interpretation.

Clinical Features

The clinical presentation of prolonged fever is heterogeneous and often non-specific, encompassing constitutional symptoms (malaise, weight loss, myalgia) alongside organ-specific manifestations driven by underlying etiology. Metabolic derangements—including hyperglycemia, hypoalbuminemia, and elevated transaminases—are frequently observed. Biomarkers such as CRP, procalcitonin, and ferritin may provide clues to the underlying cause, with markedly elevated levels suggestive of severe infection, macrophage activation syndrome, or hemophagocytic lymphohistiocytosis. The dynamic assessment of these metabolic markers in conjunction with clinical features enhances diagnostic accuracy and guides the prioritization of further investigations.

Diagnosis

Diagnostic evaluation for prolonged fever integrates clinical assessment with targeted laboratory investigations. Biomarkers play a pivotal role, with CRP and erythrocyte sedimentation rate (ESR) serving as traditional markers of inflammation. Procalcitonin has emerged as a valuable tool in distinguishing bacterial from non-bacterial causes, while elevated ferritin may indicate macrophage activation or autoimmune pathology. Metabolomic profiling using mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy offers a comprehensive view of metabolic alterations, enabling identification of disease-specific biomarker signatures. The integration of metabolic biomarkers with molecular diagnostics and imaging enhances the precision and speed of etiological diagnosis.

Treatment & Management

Management of prolonged fever is contingent upon accurate etiological identification, with supportive care addressing metabolic derangements. Biomarker-guided algorithms facilitate early initiation or de-escalation of antimicrobial therapy, minimizing unnecessary drug exposure. Correction of metabolic abnormalities—such as electrolyte disturbances, hyperglycemia, or hypoalbuminemia—is essential to optimize patient outcomes. For non-infectious etiologies, immunomodulatory agents may be guided by biomarker profiles indicative of cytokine storm or immune dysregulation. Serial monitoring of metabolic biomarkers provides an objective measure of treatment response and risk stratification.

Recent Advances / Emerging Therapies

Recent advances in high-throughput omics technologies have propelled the discovery of novel biomarkers reflecting host metabolic adaptation to prolonged fever. Metabolites such as kynurenine, neopterin, and citrulline have shown promise as indicators of immune activation, mitochondrial dysfunction, and gut barrier integrity. Multiplex biomarker panels, incorporating proteomic and metabolomic data, offer enhanced diagnostic performance over single analyte assays. Emerging therapies targeting metabolic pathways—such as mitochondrial protectants and anti-inflammatory metabolites—are under investigation for the modulation of host response in severe or refractory cases. The application of artificial intelligence to biomarker datasets holds potential for individualized risk prediction and therapeutic optimization.

Guideline Recommendations

Contemporary clinical guidelines advocate for a structured approach to the diagnosis and management of prolonged fever, incorporating the judicious use of biomarkers as adjuncts to clinical judgment. The Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommend serial assessment of CRP and procalcitonin to monitor disease trajectory and guide antimicrobial stewardship. Guidelines also endorse the integration of emerging biomarkers within research protocols and specialized clinical settings, emphasizing the need for standardized assay methodologies and evidence-based interpretation. Multidisciplinary collaboration is encouraged to ensure comprehensive evaluation and management.

Conclusion

Biomarkers of host metabolic response to prolonged fever have revolutionized the approach to diagnosis, risk stratification, and management in complex clinical scenarios. Advances in proteomic and metabolomic profiling have expanded the repertoire of available markers, enabling a more nuanced understanding of underlying pathophysiology and facilitating personalized therapeutic strategies. Ongoing research and guideline-driven implementation are essential to maximize the clinical utility of metabolic biomarkers, ultimately improving patient outcomes in the context of prolonged febrile illnesses.